Kiora Pharmaceuticals Inc.
KPRX Nasdaq
SEC CIK 1372514
Follow Kiora Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$1M
Net income
−$1.7M
−6626.6% vs same quarter last year
EPS, diluted
−$0.28
−2900% vs same quarter last year
Operating cash flow
−$557.5K
+56.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$10.8K |
| FY24 | $16M | $3.6K |
| FY23 | $0 | −$12.5K |
| FY22 | - | −$13.6M |
| FY21 | $0 | −$13.8M |
| FY20 | $12.1K | −$6.9M |
| FY19 | $2.7M | −$7.1M |
| FY18 | $1.7M | −$10.8M |
| FY17 | $407.5K | −$13.2M |
| FY16 | $669.3K | −$13.3M |
| FY15 | $0 | −$8.4M |
| FY14 | - | −$1.6M |
| FY13 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | 28.2% | 0% |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | −56960.5% | −56901.7% |
| FY19 | - | −264.2% |
| FY18 | −656.3% | −654.2% |
| FY17 | - | −3243.5% |
| FY16 | - | −1993.8% |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$10.1M |
| FY24 | $8.6M |
| FY23 | −$9.6M |
| FY22 | −$10.4M |
| FY21 | −$10.7M |
| FY20 | −$7.3M |
| FY19 | −$8.2M |
| FY18 | −$10.9M |
| FY17 | −$6.5M |
| FY16 | −$8.4M |
| FY15 | - |
| FY14 | - |
| FY13 | - |
- Kiora Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Kiora Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | 0% | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | −56901.7% | −62.2% |
| FY19 | −264.2% | −46.2% |
| FY18 | −654.2% | −49.6% |
| FY17 | −3243.5% | −45.9% |
| FY16 | −1993.8% | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |